Manatt Health senior advisor Ian Spatz spoke with WSJ Pro Venture Capital on President Trump’s recent decision to issue a series of executive orders aimed at lowering prescription drug costs, and the impact they might on investment in biotechnology. In particular, Spatz discussed one of the ...